Introduction
Stopping a GLP-1 medicine often leads to weight regain, on average, in withdrawal studies. In the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-associated weight loss during the following year.
In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% from randomization through week 88, while continued treatment produced a further 5.5% average loss.
What semaglutide withdrawal data show
The STEP 1 extension followed a subset after weekly semaglutide 2.4 mg and the lifestyle intervention ended. Average body weight rose by 11.6 percentage points over the following year, described by the authors as about two-thirds of the prior loss. Several cardiometabolic improvements moved toward baseline during follow-up.
We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure
LIVE CATALOGCurrent telehealth prices and providers
Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $349, checked 20 October 2026 a month after 2 months at $199/month; plus $99/month care Visit provider Affiliate link · we may earn a commission | Wegovy® pen · Weekly injection · medication included Medication: $199/month for the first two months for eligible new self-pay patients at 0.25 or 0.5 mg, then $349/month. Offer ends December 31, 2026. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,349, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Wegovy® · Weekly branded injection · medication included The weight-loss category card prints $1,349 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,695, checked 22 October 2026 a month, continuing Visit provider | Wegovy® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($199–$349/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
- MEDGm: $99 membership + medication cost (medication total not published)Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $299, checked 20 October 2026 a month, continuing; plus $99/month care Visit provider Affiliate link · we may earn a commission | Zepbound® KwikPen · Weekly injection · medication included Medication dose prices: $299/month at 2.5 mg; $398 at 5 mg; $499 at 7.5 mg; $698 at 10, 12.5 or 15 mg. The calculation uses the 2.5 mg price; a dose change changes the total. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,069, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Zepbound® · Weekly branded injection · medication included The weight-loss category card prints $1,069 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,399, checked 22 October 2026 a month, continuing Visit provider | Zepbound® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($299–$449/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Gala Health | $1,299, checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly injection · medication included The Ozempic product page says From $1,299/month, cash price. It says insurance may reduce the cost. That page shows no other dollar price. Price source · checked 21 October 2026 |
| #2 RxSpan MD | $1,299, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly branded injection · medication included The weight-loss category card prints $1,299 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- MEDGm: $171 membership + medication cost (medication total not published)Medication or membership billed separately
- Shed Rx: Starting at $599/mo. Hero $149 is CMS template bleed.Last checked 14 Sept 2026Medication included as published
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- RxSpan MD: $1,069 / month; org catalog also marks this SKU sold outLast checked 14 Sept 2026Medication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What tirzepatide maintenance data show
SURMOUNT-4 included a 36-week tirzepatide lead-in, then randomized participants to continue tirzepatide or switch to placebo. From randomization to week 88, the continued-treatment group had a further 5.5% average weight reduction, while the placebo-switch group had 14.0% average regain.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
How to plan a treatment change
A treatment change is a good time to review the reason for stopping, diabetes medicines, symptom history, nutrition and activity support, access, and future goals. People using insulin or a sulfonylurea need a coordinated diabetes plan before a GLP-1 medicine changes because the rest of the regimen may need reassessment.
Plan the transition
A clinician can review why treatment is changing, glucose goals, other medicines, prior symptoms, nutrition and activity support, access, and preference.
Diabetes adds medication questions
People using insulin or a secretagogue need a coordinated plan before a GLP-1 change.
Avoid abrupt self-switching
A price change, supply concern, or social-media suggestion does not replace a product-specific clinical review.
What the cited sources establish
The withdrawal evidence is study-specific. The STEP 1 extension followed a semaglutide subgroup after treatment and lifestyle intervention stopped, while SURMOUNT-4 randomized participants after a tirzepatide lead-in to continue treatment or switch to placebo. Both studies inform maintenance conversations, but neither provides a personal stopping timetable.
The two withdrawal studies differ in design, which matters when reading their numbers. STEP 1 extension participants stopped both semaglutide and the trial lifestyle intervention, while SURMOUNT-4 participants first completed a tirzepatide lead-in before randomization. The shared practical point is that maintenance deserves planning before an interruption happens, especially when diabetes care, adverse effects, cost, or a pregnancy plan is driving the change.
Before a planned interruption, the care team can decide what outcome will be watched next. For some people that will include body weight and appetite; for people with diabetes it can also include glucose management and the rest of the diabetes regimen. A record of prior adverse effects and the reason for the change helps distinguish a short access disruption from a broader change in treatment strategy. The withdrawal trials support preparing for that transition instead of treating it as an afterthought.
Questions that change the next review
A stopping discussion should identify why the change is being considered and what else must change with it. Diabetes medicines, symptom history, nutrition support, access, pregnancy plans, and the possibility of future treatment alternatives all belong in the handoff plan. The relevant clinician can also explain which outcomes to follow after a transition.
The transition plan can name the clinician responsible for diabetes medicines, the follow-up timing, and the symptoms or outcomes that warrant earlier contact. That turns trial withdrawal findings into a usable care conversation.
Product details that still need verification
Regain averages do not prove that one person will regain at the same rate or that continuing treatment is always the right choice. This article does not supply a taper, restart schedule, or substitute regimen. A supply or price disruption still requires product-specific clinical review before a medication change.
Withdrawal evidence is an average, not an individual's exact outcome. Stopping is not a personal failure. Diabetes medicines need review before a GLP-1 change. Do not restart, taper, or switch from a generic schedule. Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about What Happens When You Stop a GLP-1? What Withdrawal Trials Show About Weight Regain?
- Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led. The next step is a clinician-led review of the exact product and your situation.
Already on a wegovy plan? See which of 4 providers charge less than yours
Starting from scratch? How to get Ozempic injection online
Sources
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry